Evidence map›Paper›PMID 41262473›Full record

ArticleFrontiers in neuroscience2025

NMPhenogen: a comprehensive database for genotype-phenotype correlation in neuromuscular genetic disorders.

Usha Manjunath, Venkatesh R, Sacheta Sudhendra Kulkarni, Harshatha N Reddy, Anupama Anil, Rakesh Kumar Mishra, Gayatri Rangarajan Iyer

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Usha Manjunath *Tata Institute for Genetics and Society, Gandhi Krishi Vignana Kendra Campus, Bengaluru, Karnataka, India.
Venkatesh R *Tata Institute for Genetics and Society, Gandhi Krishi Vignana Kendra Campus, Bengaluru, Karnataka, India.
Sacheta Sudhendra KulkarniTata Institute for Genetics and Society, Gandhi Krishi Vignana Kendra Campus, Bengaluru, Karnataka, India.
Harshatha N ReddyTata Institute for Genetics and Society, Gandhi Krishi Vignana Kendra Campus, Bengaluru, Karnataka, India.
Anupama AnilTata Institute for Genetics and Society, Gandhi Krishi Vignana Kendra Campus, Bengaluru, Karnataka, India.
Rakesh Kumar MishraTata Institute for Genetics and Society, Gandhi Krishi Vignana Kendra Campus, Bengaluru, Karnataka, India.
Gayatri Rangarajan IyerTata Institute for Genetics and Society, Gandhi Krishi Vignana Kendra Campus, Bengaluru, Karnataka, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromuscular genetic disorders (NMGDs) are genetically and clinically diverse group of inherited diseases that affect approximately 1 in 1,000 people worldwide with a calculated prevalence of 37 per 10,000 in the general population. These disorders arise from a variety of genetic changes such as insertions, deletions, duplications and expansions of repeats in more than 747 nuclear and mitochondrial genes critical for the function of peripheral nerves, motor neurons, neuromuscular junctions or skeletal muscles, leading to progressive weakness and degeneration of muscles. Major subtypes include muscular dystrophies, congenital myopathies, motor neuron diseases, peripheral neuropathies, and mitochondrial myopathies. Clinical presentation of NMGDs is highly variable in the age of onset, severity and pattern of muscle involvement, often leading to prolonged and complex diagnostic process. Conventional diagnostic methods have relied on clinical history, physical examination and invasive procedures like muscle biopsy. But the development of next-generation sequencing (NGS) has transformed diagnostics by enabling comprehensive analysis of NMGD-related genes. Despite this advancement, interpreting the numerous variants identified by NGS remains challenging. The guidelines of the American College of Medical Genetics and Genomics (ACMG) offer a standardized approach to variant classification as pathogenic, likely pathogenic, variant of uncertain significance, likely benign and benign. However, this requires the integration of complex evidence from population data, computational predictions, and functional assays. The major challenge is the robust correlation of genotypic information with the huge phenotypic range of NMGDs which is a task complicated by the unavailability of population-specific genetic databases. To address these issues, we have developed NMPhenogen (https://gi-lab-tigs.github.io/Homepage/), a new database designed to enhance the diagnosis and understanding of NMGDs. NMPhenogen is a centralized repository for data related to NMGD-associated genes and variants along with their clinical presentations. It includes two primary modules: NMPhenoscore, which enhances disease-phenotype correlations, and a Variant classifier, which facilitates standardized variant classification based on published guidelines. This combined resource aims to streamline the diagnostic process, support clinical decision-making, and eventually contribute to improving patient care and genetic counseling.

Indexed as

ACMGdisease prioritizationneuromuscular disordersNMGDNMPhenoscorevariant classificationvariant classifiervariant interpretation tool

Identifiers

PMID41262473
PMCPMC12623376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.